Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
A panel at OneMedForum NY 2011 will explore strategic planning considerations in the process of getting approval and reimbursement.
Member Spotlight
June 23-24 OneMedForum New York
OneMedPlace Trans-Atlantic Conference on June 23rd-24th is a gathering of fast growing, emerging healthcare and life science companies in Europe and North America. Its sixth […]
Rib-X Pharmaceuticals’ Nobel Prize Winning Platform Combats Serious Infections
The antibiotic market is expected to reach $45 billion by 2012 driven by the deficiencies of currently available antibiotics.
Small Bone Innovations Addresses Unmet Needs in Joint Replacement
Orthopedic companies have focused on developing devices for large bone trauma, leaving the small bone and joint field lacking.
Hepregen Awarded $500,000 Massachusetts Life Sciences Center Grant
Hepregen, a leading provider of bioengineered solutions that increase success in drug development, was awarded a $500,000 grant as part of the Small Business Matching Grants program
GlySure’s Technology May Break Barrier For Tight Control And Automated Glucose Monitoring
GlySure’s technology enables a healthcare facility to implement tight glycemic control and intensive insulin therapy.
Advanced Cardiac Therapeutics Studies Innovative Catheter System To Treat Arrythmias
ACT recently announced that the first patients have been enrolled in a CE Mark clinical trial of the safety and performance of the company’s TEMPASURE cardiac ablation catheter.
Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer
The fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by UV exposure or excessive sun burn.
Tianyin Pharmaceuticals Receives China’s SFDA Approval for Its Anti-Diabetic Drug Gliclazide
In 2010, there were 95 million cases of diabetes in China, of which, 52 million and 43 million were found in rural and urban areas, respectively.
Threshold Pharmaceuticals Selectively Targets Tumor Cells in Cancer Therapeutics
Threshold Pharmaceuticals takes advantage of the differences in metabolic activity between cancerous and normal, healthy biological tissue.